Hangzhou Tigermed Consulting Co., Ltd.
Hangzhou Tigermed Consulting Co., Ltd. 3347.HK Peers
See (3347.HK) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
---|---|---|---|---|---|---|
3347.HK | $25.35 | -5.23% | 34.35B | 60.36 | $0.42 | +2.67% |
2359.HK | $63.20 | -0.94% | 186.75B | 15.05 | $4.20 | +3.68% |
2268.HK | $38.15 | -0.26% | 45.88B | 42.39 | $0.90 | N/A |
6127.HK | $9.70 | +0.31% | 11.92B | 17.64 | $0.55 | +1.99% |
2325.HK | $3.50 | N/A | 2.05B | -2.43 | -$1.44 | +0.62% |
6667.HK | $7.20 | -0.69% | 1.61B | 42.35 | $0.17 | N/A |
8037.HK | $0.70 | +14.75% | 683.01M | -3.33 | -$0.21 | N/A |
8225.HK | $0.16 | -4.19% | 159.26M | 8.00 | $0.02 | N/A |
0928.HK | $0.08 | +5.33% | 146.18M | 7.90 | $0.01 | N/A |
Stock Comparison
3347.HK vs 2359.HK Comparison
3347.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3347.HK stands at 34.35B. In comparison, 2359.HK has a market cap of 186.75B. Regarding current trading prices, 3347.HK is priced at $25.35, while 2359.HK trades at $63.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3347.HK currently has a P/E ratio of 60.36, whereas 2359.HK's P/E ratio is 15.05. In terms of profitability, 3347.HK's ROE is +0.02%, compared to 2359.HK's ROE of +0.19%. Regarding short-term risk, 3347.HK is more volatile compared to 2359.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 3347.HK.